22-Dec-2025
No headlines found.
Bausch + Lomb Announces Two Board of Directors Appointments
Business Wire (Wed, 17-Dec 4:30 PM ET)
Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
Business Wire (Fri, 12-Dec 4:49 PM ET)
Bausch + Lomb to Participate in Citi Global Healthcare Conference
Business Wire (Tue, 18-Nov 4:30 PM ET)
NYSE Content Advisory: Pre-Market Update + TKO and Polymarket Announce Partnership
PRNewswire (Thu, 13-Nov 8:55 AM ET)
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
Business Wire (Thu, 13-Nov 7:00 AM ET)
Business Wire (Mon, 10-Nov 6:59 AM ET)
Bausch + Lomb to Hold Investor Day on Nov. 13
Business Wire (Mon, 3-Nov 4:30 PM ET)
Bausch + Lomb Announces Third-Quarter 2025 Results
Business Wire (Wed, 29-Oct 6:58 AM ET)
Business Wire (Mon, 29-Sep 7:15 AM ET)
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Bausch & Lomb trades on the NYSE stock market under the symbol BLCO.
As of December 22, 2025, BLCO stock price declined to $16.92 with 198,515 million shares trading.
BLCO has a beta of 1.02, meaning it tends to be more sensitive to market movements. BLCO has a correlation of 0.20 to the broad based SPY ETF.
BLCO has a market cap of $5.99 billion. This is considered a Mid Cap stock.
Last quarter Bausch & Lomb reported $1 billion in Revenue and $.18 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, BLCO traded as high as $21.95 and as low as $10.45.
The top ETF exchange traded funds that BLCO belongs to (by Net Assets): MGMT, DFAX, DFIC, GUSA.
BLCO has underperformed the market in the last year with a return of -6.0%, while SPY returned +17.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BLCO shares. However, BLCO has outperformed the market in the last 3 month and 2 week periods, returning +11.0% and +2.2%, while SPY returned +3.0% and +0.5%, respectively. This indicates BLCO has been having a stronger performance recently.
BLCO support price is $16.62 and resistance is $17.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLCO shares will trade within this expected range on the day.
